Elaheh Emadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elaheh Emadi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Alireza Mousavian
Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications- Pejman Porouhan
Sabzevar University of Medical Sciences
2 shared publications - Seyed Alireza Javadinia
Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
2 shared publications - Ali Shams
Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication - Arezoo Khoradmehr
Persian Gulf Marine Biotechnology Research Sciences Center, The Persian Gulf Biomedical Research Sciences Institute, Bushehr University of Medical Sciences, Bushehr, 75147, Iran, bpums.ac.ir
1 shared publication - Babak PeyroShabany
Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
1 shared publication
Latest Publications
- 18 August 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-16
Melatonin supplementation for sleep disturbance in breast cancer survivors: a randomized, double-blind, placebo-controlled trial
1. Breast cancer remains the most common malignancy among women worldwide and a leading cause of cancer-related mortality (Bray et al. 2024). Despite substantial advances in diagnosis and treatment...
- 18 August 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-16
Melatonin supplementation for sleep disturbance in breast cancer survivors: a randomized, double-blind, placebo-controlled trial
1. Breast cancer remains the most common malignancy among women worldwide and a leading cause of cancer-related mortality (Bray et al. 2024). Despite substantial advances in diagnosis and treatment...
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-17
Platelet-Rich Plasma Fibrin Glue Dressing Combined with a Novel Repairing Gel for Healing Recalcitrant Diabetic Foot Ulcers: Findings from an Exploratory Randomized Pilot Trial
Purpose: Recalcitrant diabetic foot ulcers (DFUs) remain difficult to heal and impose substantial clinical and economic burdens. This exploratory, four-arm, parallel-group randomized pilot trial aimed to evaluate whether combining platelet-rich plasma-fibrin glue (PRP‑FG) with a novel repairing gel enhances healing outcomes in DFUs compared with standard care and single‑agent therapies. Patients and Methods: In this study, twenty patients with DFUs unresponsive to at least four weeks of standard treatment were randomized using computer-generated blocks with allocation concealment to receive PRP‑FG alone, repairing gel alone, the combination therapy, or standard care. Allogeneic PRP‑FG was prepared by gradient‑density centrifugation. The repairing gel contained multiple active components, including vitamins A, B3, and C, collagen, glycine, organic acids, sodium alginate, carboxymethyl cellulose, benzoic acid, gentian violet, methylene blue, triethanolamine, bromelain, allantoin, and dimethyl sulfoxide. Wound healing rate over 12 weeks served as the primary outcome, assessed weekly by a blinded evaluator. Results: Nineteen patients completed the 12‑week follow‑up. Complete epithelialization occurred in 100% (5/5) of participants receiving the combined therapy, 20% (1/5) of those receiving the repairing gel alone, and 0% (0/5) in the PRP‑FG alone and standard care groups. The combined therapy significantly accelerated ulcer healing compared with all other groups (p < 0.05). These findings are preliminary and derived from a small pilot sample. No serious adverse events were observed. Conclusion: This exploratory pilot trial suggests that combined PRP‑FG and repairing gel therapy may promote superior healing of recalcitrant DFUs compared with standard care or single‑agent treatments. Larger, multicenter clinical trials are warranted to validate these preliminary findings.
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-17
Open AccessPlatelet-Rich Plasma Fibrin Glue Dressing Combined with a Novel Repairing Gel for Healing Recalcitrant Diabetic Foot Ulcers: Findings from an Exploratory Randomized Pilot Trial
Purpose: Recalcitrant diabetic foot ulcers (DFUs) remain difficult to heal and impose substantial clinical and economic burdens. This exploratory, four-arm, parallel-group randomized pilot trial aimed to evaluate whether combining platelet-rich plasma-fibrin glue (PRP‑FG) with a novel repairing gel enhances healing outcomes in DFUs compared with standard care and single‑agent therapies. Patients and Methods: In this study, twenty patients with DFUs unresponsive to at least four weeks of standard treatment were randomized using computer-generated blocks with allocation concealment to receive PRP‑FG alone, repairing gel alone, the combination therapy, or standard care. Allogeneic PRP‑FG was prepared by gradient‑density centrifugation. The repairing gel contained multiple active components, including vitamins A, B3, and C, collagen, glycine, organic acids, sodium alginate, carboxymethyl cellulose, benzoic acid, gentian violet, methylene blue, triethanolamine, bromelain, allantoin, and dimethyl sulfoxide. Wound healing rate over 12 weeks served as the primary outcome, assessed weekly by a blinded evaluator. Results: Nineteen patients completed the 12‑week follow‑up. Complete epithelialization occurred in 100% (5/5) of participants receiving the combined therapy, 20% (1/5) of those receiving the repairing gel alone, and 0% (0/5) in the PRP‑FG alone and standard care groups. The combined therapy significantly accelerated ulcer healing compared with all other groups (p < 0.05). These findings are preliminary and derived from a small pilot sample. No serious adverse events were observed. Conclusion: This exploratory pilot trial suggests that combined PRP‑FG and repairing gel therapy may promote superior healing of recalcitrant DFUs compared with standard care or single‑agent treatments. Larger, multicenter clinical trials are warranted to validate these preliminary findings.
- Open Access
- 15 July 2026
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 010 (03) , 1-17
Novel SLITRK6 Nonsense Mutation in an Iranian Family with Autosomal Recessive Syndromic Hearing Loss
SLITRK6 is essential for inner-ear neuronal survival and retinal development, and pathogenic variants in this gene cause syndromic sensorineural hearing loss (HL) with high myopia. This study aimed to identify the genetic basis of HL and myopia in a consanguineous Iranian family with two affected children and to characterize the molecular consequences of the detected variant. One sibling with bilateral congenital HL and myopia was evaluated using whole-exome sequencing (WES). Common variants (MAF >1%) were excluded, and rare exonic changes were prioritized. Variant pathogenicity was assessed according to ACMG guidelines, and segregation was confirmed by Sanger sequencing in two affected children and their parents. ProtParam was used to compare physicochemical properties of wild-type and truncated proteins, and STRING was applied to assess predicted protein-protein interactions. WES identified a novel homozygous nonsense variant in SLITRK6, NM_032229.3:c.1795C>T (p.Arg599Ter), located in exon 2. The parents were heterozygous carriers, and the variant was ultra-rare in public databases. In silico analyses predicted that the premature termination codon produces a truncated protein with loss-of-function effects. These findings are consistent with previously described SLITRK6-associated HL with myopia. We report a novel likely pathogenic SLITRK6 variant associated with congenital HL and myopia in an Iranian family. The predicted loss-of-function supports an important role for SLITRK6 in auditory and visual system development. Further studies are needed to elucidate the molecular mechanisms underlying SLITRK6-related disorders.
- 15 July 2026
- Published by LIDSEN Publishing Inc in OBM Genetics
- Vol. 010 (03) , 1-17
Open AccessNovel SLITRK6 Nonsense Mutation in an Iranian Family with Autosomal Recessive Syndromic Hearing Loss
SLITRK6 is essential for inner-ear neuronal survival and retinal development, and pathogenic variants in this gene cause syndromic sensorineural hearing loss (HL) with high myopia. This study aimed to identify the genetic basis of HL and myopia in a consanguineous Iranian family with two affected children and to characterize the molecular consequences of the detected variant. One sibling with bilateral congenital HL and myopia was evaluated using whole-exome sequencing (WES). Common variants (MAF >1%) were excluded, and rare exonic changes were prioritized. Variant pathogenicity was assessed according to ACMG guidelines, and segregation was confirmed by Sanger sequencing in two affected children and their parents. ProtParam was used to compare physicochemical properties of wild-type and truncated proteins, and STRING was applied to assess predicted protein-protein interactions. WES identified a novel homozygous nonsense variant in SLITRK6, NM_032229.3:c.1795C>T (p.Arg599Ter), located in exon 2. The parents were heterozygous carriers, and the variant was ultra-rare in public databases. In silico analyses predicted that the premature termination codon produces a truncated protein with loss-of-function effects. These findings are consistent with previously described SLITRK6-associated HL with myopia. We report a novel likely pathogenic SLITRK6 variant associated with congenital HL and myopia in an Iranian family. The predicted loss-of-function supports an important role for SLITRK6 in auditory and visual system development. Further studies are needed to elucidate the molecular mechanisms underlying SLITRK6-related disorders.
- 1 June 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (Sup6b)
Platelet-rich-fibrin repairing gel plus oral methylene blue for hard-to-heal diabetic foot ulcers: a pilot study
Objective: Hard-to-heal (chronic) diabetic foot ulcers (DFUs) are a major healthcare challenge worldwide. A combinatorial strategy may offer effective therapeutic potential. The present study investigated the effectiveness of a repairing gel containing platelet-rich plasma-fibrin glue (PRP-FG) and oral methylene blue (MB, administered as leucomethylene blue (LMB)) for hard-to-heal DFUs. Method: This single-centre, self-controlled pilot study was conducted on patients with DFUs who met the inclusion criteria. All patients had not responded to standard therapies for at least four weeks. For 12 weeks, they received the repairing gel dressing and 35mg of MB dissolved in 200ml of infant formula milk (administered as LMB). Participants had weekly follow-up visits to assess their wound healing progress. Results: A total of six patients took part; four participants completed the 12 weeks of treatment. At the end of the treatment period, the new intervention was compared to previous standard care. Participants demonstrated a reduced wound area and improved wound bed condition. A significant increase in transcutaneous oxygen tension was observed, indicating improved tissue oxygenation (p=0.034). Additionally, participants experienced reductions in wound exudate, pain and malodour within the first week of treatment. No serious adverse events were reported during the follow-up period. Conclusion: The findings of this pilot study suggest that combined therapy using a PRP-FG-containing repair gel and oral MB (as LMB) may provide a safe and effective approach to treating hard-to-heal DFUs. Further research is warranted to confirm these findings.
- 1 June 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (Sup6b)
Platelet-rich-fibrin repairing gel plus oral methylene blue for hard-to-heal diabetic foot ulcers: a pilot study
Objective: Hard-to-heal (chronic) diabetic foot ulcers (DFUs) are a major healthcare challenge worldwide. A combinatorial strategy may offer effective therapeutic potential. The present study investigated the effectiveness of a repairing gel containing platelet-rich plasma-fibrin glue (PRP-FG) and oral methylene blue (MB, administered as leucomethylene blue (LMB)) for hard-to-heal DFUs. Method: This single-centre, self-controlled pilot study was conducted on patients with DFUs who met the inclusion criteria. All patients had not responded to standard therapies for at least four weeks. For 12 weeks, they received the repairing gel dressing and 35mg of MB dissolved in 200ml of infant formula milk (administered as LMB). Participants had weekly follow-up visits to assess their wound healing progress. Results: A total of six patients took part; four participants completed the 12 weeks of treatment. At the end of the treatment period, the new intervention was compared to previous standard care. Participants demonstrated a reduced wound area and improved wound bed condition. A significant increase in transcutaneous oxygen tension was observed, indicating improved tissue oxygenation (p=0.034). Additionally, participants experienced reductions in wound exudate, pain and malodour within the first week of treatment. No serious adverse events were reported during the follow-up period. Conclusion: The findings of this pilot study suggest that combined therapy using a PRP-FG-containing repair gel and oral MB (as LMB) may provide a safe and effective approach to treating hard-to-heal DFUs. Further research is warranted to confirm these findings.
- 19 October 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (1) , 5-12
Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial
- 19 October 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (1) , 5-12
Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial
- Open Access
- 9 May 2023
- Published by Taylor & Francis in Immunological Medicine
- Vol. 46 (4) , 1-5
The effects of grapes and their products on immune system: a review
Immune system plays a significant role in preventing and controlling diseases. Some studies reported the beneficial effects of grapes and their products on immunity. However, their results are controversial. This review aimed to discuss the effects of grapes and their products on immune system and their mechanisms of action. Although various in-vio and in-vitro studies and some human studies suggested that grapes and their products may help to improve the immune system’s function, clinical trials in this area are limited and inconsistent. In conclusions, although, consumption of grapes and their products may help to having a healthy immune syste, further studies particularly human studies are required to clarify the precise effects of them and their mechanisms regarding immune system.
- 9 May 2023
- Published by Taylor & Francis in Immunological Medicine
- Vol. 46 (4) , 1-5
Open AccessThe effects of grapes and their products on immune system: a review
Immune system plays a significant role in preventing and controlling diseases. Some studies reported the beneficial effects of grapes and their products on immunity. However, their results are controversial. This review aimed to discuss the effects of grapes and their products on immune system and their mechanisms of action. Although various in-vio and in-vitro studies and some human studies suggested that grapes and their products may help to improve the immune system’s function, clinical trials in this area are limited and inconsistent. In conclusions, although, consumption of grapes and their products may help to having a healthy immune syste, further studies particularly human studies are required to clarify the precise effects of them and their mechanisms regarding immune system.
- 29 April 2021
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 97 (2) , 136-142
Appropriate fixative for MEM-G/9 staining of cultured human HLA-G-positive JEG-3 trophoblast tumor cells
Human leukocyte antigen (HLA-G) participates in immunosuppression and is useful for prenatal diagnostics. Isolation of fetal cells positive for HLA-G by HLA-G antibody conjugated nanoparticles from the cervix of pregnant women is the basis for non-invasive prenatal testing. Endocervical specimens are fixed in transport medium before isolation using antibody conjugated nanoparticles. Staining of HLA-G using MEM-G/9 antibody, however, is restricted to unfixed cells. We investigated the effect of several fixatives on the interaction of HLA-G with MEM-G/9 in the HLA-G-positive cell line, JEG-3. We investigated absolute methanol, 1:1 acetate buffer:methanol, Pap solution and paraformaldehyde. The effects of these fixatives were evaluated using immunofluorescence. We found no MEM-G/9 surface staining of methanol fixed cells. Approximately 40% of JEG-3 cells fixed with paraformaldehyde failed to stain. Nearly all cells were stained with MEM-G/9 following fixation with acetate buffer:methanol or Pap solution. Our findings indicate the importance of using an appropriate fixative for preserving HLA-G cell surface antigen for studies using the MEM-G/9 antibody.
- 29 April 2021
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 97 (2) , 136-142
Appropriate fixative for MEM-G/9 staining of cultured human HLA-G-positive JEG-3 trophoblast tumor cells
Human leukocyte antigen (HLA-G) participates in immunosuppression and is useful for prenatal diagnostics. Isolation of fetal cells positive for HLA-G by HLA-G antibody conjugated nanoparticles from the cervix of pregnant women is the basis for non-invasive prenatal testing. Endocervical specimens are fixed in transport medium before isolation using antibody conjugated nanoparticles. Staining of HLA-G using MEM-G/9 antibody, however, is restricted to unfixed cells. We investigated the effect of several fixatives on the interaction of HLA-G with MEM-G/9 in the HLA-G-positive cell line, JEG-3. We investigated absolute methanol, 1:1 acetate buffer:methanol, Pap solution and paraformaldehyde. The effects of these fixatives were evaluated using immunofluorescence. We found no MEM-G/9 surface staining of methanol fixed cells. Approximately 40% of JEG-3 cells fixed with paraformaldehyde failed to stain. Nearly all cells were stained with MEM-G/9 following fixation with acetate buffer:methanol or Pap solution. Our findings indicate the importance of using an appropriate fixative for preserving HLA-G cell surface antigen for studies using the MEM-G/9 antibody.